CompletedPhase 1NCT00351975
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Studying Acute myeloid leukemia with t(9;11)(p22;q23)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Olatoyosi OdenikeUniversity of Chicago Comprehensive Cancer Center
- Intervention
- Belinostat(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2013
Study locations (4)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
- Princess Margaret Hospital, Cashmere, Canterbury, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00351975 on ClinicalTrials.gov